Published in Gene Therapy Weekly, November 15th, 2001
Scientists at the University of Tennessee, Knoxville, have found that secondary lymphoid tissue chemokine (SLC) and Epstein-Barr virus-induced molecule 1 ligand chemokine (ELC) augment the effectiveness of herpes simplex virus DNA vaccines. These chemokines, codelivered via plasmid DNA, might be an important adjuvant for genetic vaccines used to battle other infectious diseases or cancer, researchers propose.
Both SLC and ELC pave the way for effective immune...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.